[go: up one dir, main page]

WO1998047497A3 - Methodes et compositions afferentes aux fins de la prevention et du traitement de troubles immunologiques, de maladies et d'infections a caractere inflammatoire - Google Patents

Methodes et compositions afferentes aux fins de la prevention et du traitement de troubles immunologiques, de maladies et d'infections a caractere inflammatoire Download PDF

Info

Publication number
WO1998047497A3
WO1998047497A3 PCT/US1998/008164 US9808164W WO9847497A3 WO 1998047497 A3 WO1998047497 A3 WO 1998047497A3 US 9808164 W US9808164 W US 9808164W WO 9847497 A3 WO9847497 A3 WO 9847497A3
Authority
WO
WIPO (PCT)
Prior art keywords
prevention
compositions
treatment
methods
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/008164
Other languages
English (en)
Other versions
WO1998047497A2 (fr
Inventor
Thomas E Fleming
Herbert C Mansmann Jr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fleming and Co Pharmaceuticals
Original Assignee
Fleming and Co Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/844,909 external-priority patent/US5939394A/en
Priority claimed from US08/844,988 external-priority patent/US5922765A/en
Application filed by Fleming and Co Pharmaceuticals filed Critical Fleming and Co Pharmaceuticals
Priority to AU71505/98A priority Critical patent/AU7150598A/en
Publication of WO1998047497A2 publication Critical patent/WO1998047497A2/fr
Publication of WO1998047497A3 publication Critical patent/WO1998047497A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Cette invention a trait à des compositions et aux méthodes afférentes aux fins de la prévention et/ou du traitement d'affections allergiques, de maladies auto-immunes, de chocs septiques ou de maladies infectieuses. Il est utilisé, dans le cadre de ces méthodes, du gluconate de magnésium seul ou associé à un ou plusieurs antioxydants ou à un agent anti-inflammatoire. Cette invention concerne également l'inhibition de la production de quantités inopportunes de médiateurs des lipides et de cytokines.
PCT/US1998/008164 1997-04-23 1998-04-23 Methodes et compositions afferentes aux fins de la prevention et du traitement de troubles immunologiques, de maladies et d'infections a caractere inflammatoire Ceased WO1998047497A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU71505/98A AU7150598A (en) 1997-04-23 1998-04-23 Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/844,909 US5939394A (en) 1996-01-18 1997-04-23 Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections
US08/844,909 1997-04-23
US08/844,988 US5922765A (en) 1996-01-18 1997-04-23 Methods and compositions for the prevention and treatment of muscle cramps and improving muscular strength

Publications (2)

Publication Number Publication Date
WO1998047497A2 WO1998047497A2 (fr) 1998-10-29
WO1998047497A3 true WO1998047497A3 (fr) 1999-01-21

Family

ID=27126538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/008164 Ceased WO1998047497A2 (fr) 1997-04-23 1998-04-23 Methodes et compositions afferentes aux fins de la prevention et du traitement de troubles immunologiques, de maladies et d'infections a caractere inflammatoire

Country Status (1)

Country Link
WO (1) WO1998047497A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1313567B1 (it) * 1999-07-27 2002-09-09 Zambon Spa Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
DE10349115A1 (de) * 2003-10-22 2005-06-16 Biosyn Arzneimittel Gmbh Kombinationspräparat zur Behandlung der Sepsis
WO2014022886A1 (fr) * 2012-08-08 2014-02-13 Fischer Karen Jane Procédé, utilisation et composition de complément alimentaire pour au moins traiter un trouble atopique ou non-atopique chez un patient

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3307382A1 (de) * 1983-03-02 1984-09-06 Hans-Peter 8022 Grünwald Walter Arzneimittel, geeignet zur behandlung von entzuendlichen veraenderungen der bronchialschleimhaut
DE3517916A1 (de) * 1985-05-18 1986-11-20 Krüger GmbH & Co KG, 5060 Bergisch Gladbach Vitamin-e-brausetabletten
US5002780A (en) * 1987-07-31 1991-03-26 Caola Kozmetikai Es Haztartasvegyipari Vallalat Magnesium salt of a fatty acid acyl lactylate
FR2688133A1 (fr) * 1992-03-06 1993-09-10 Plantes Tropicales Lab Composition d'hygiene a base d'eau de mer.
CH684630A5 (fr) * 1992-08-21 1994-11-15 Danielle Girardet Composition pharmaceutique à base d'oligo-éléments.
WO1995028937A1 (fr) * 1994-04-20 1995-11-02 Béres Export-Import Rt. Concentre aqueux et son procede de preparation
EP0705542A1 (fr) * 1994-09-21 1996-04-10 Sandoz Nutrition Ltd. Composition diététique destinée à des adolescents
WO1996019182A1 (fr) * 1994-12-21 1996-06-27 Cosmederm Technologies Formulations et procedes pour diminuer l'irritation de la peau
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
EP0739629A1 (fr) * 1995-04-28 1996-10-30 Ravi Shrivastava Nouvelles associations comprenant du (-)hydroxycitrate et présentant notamment de nouvelles activités thérapeutiques
WO1997025959A2 (fr) * 1996-01-18 1997-07-24 Fleming & Company, Pharmaceuticals Compositions et procedes s'appliquant a la prevention et au traitement de l'atherosclerose et des lesions consecutives a des perfusions au moyen de sels de magnesium
WO1997026894A1 (fr) * 1996-01-25 1997-07-31 Weglicki William B Gluconate de magnesium intraveineux pour le traitement d'etats causes par un stress oxydant imputable a la repartition des radicaux libres
US5681554A (en) * 1995-06-28 1997-10-28 Cosmair, Inc. Composition for treating hair and method for using the same

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3307382A1 (de) * 1983-03-02 1984-09-06 Hans-Peter 8022 Grünwald Walter Arzneimittel, geeignet zur behandlung von entzuendlichen veraenderungen der bronchialschleimhaut
DE3517916A1 (de) * 1985-05-18 1986-11-20 Krüger GmbH & Co KG, 5060 Bergisch Gladbach Vitamin-e-brausetabletten
US5002780A (en) * 1987-07-31 1991-03-26 Caola Kozmetikai Es Haztartasvegyipari Vallalat Magnesium salt of a fatty acid acyl lactylate
FR2688133A1 (fr) * 1992-03-06 1993-09-10 Plantes Tropicales Lab Composition d'hygiene a base d'eau de mer.
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
CH684630A5 (fr) * 1992-08-21 1994-11-15 Danielle Girardet Composition pharmaceutique à base d'oligo-éléments.
WO1995028937A1 (fr) * 1994-04-20 1995-11-02 Béres Export-Import Rt. Concentre aqueux et son procede de preparation
EP0705542A1 (fr) * 1994-09-21 1996-04-10 Sandoz Nutrition Ltd. Composition diététique destinée à des adolescents
WO1996019182A1 (fr) * 1994-12-21 1996-06-27 Cosmederm Technologies Formulations et procedes pour diminuer l'irritation de la peau
EP0739629A1 (fr) * 1995-04-28 1996-10-30 Ravi Shrivastava Nouvelles associations comprenant du (-)hydroxycitrate et présentant notamment de nouvelles activités thérapeutiques
US5681554A (en) * 1995-06-28 1997-10-28 Cosmair, Inc. Composition for treating hair and method for using the same
WO1997025959A2 (fr) * 1996-01-18 1997-07-24 Fleming & Company, Pharmaceuticals Compositions et procedes s'appliquant a la prevention et au traitement de l'atherosclerose et des lesions consecutives a des perfusions au moyen de sels de magnesium
WO1997026894A1 (fr) * 1996-01-25 1997-07-31 Weglicki William B Gluconate de magnesium intraveineux pour le traitement d'etats causes par un stress oxydant imputable a la repartition des radicaux libres

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERKOW: "MERCK MANUAL OF DIAGNOSIS AND THERAPY", 1987, MERCK SHARP & DOHME RESEARCH LABORATORIES, RAHWAY, N.J., XP002080013, 14658 *
MANSMANN H C JR: "Manifestation of concurrent intracellular magnesium deficiency in symptomatic allergic patients.", SMETANA, R. (ED.). ADVANCES IN MAGNESIUM RESEARCH, 1. MAGNESIUM IN CARDIOLOGY;FIFTH EUROPEAN MAGNESIUM CONGRESS, VIENNA, AUSTRIA, 1995. XIII+617P. JOHN LIBBEY AND CO. LTD.: LONDON, ENGLAND, UK. 0 (0). 1997. 308-312. ISBN: 0-86196-555-8, XP002080011 *
SARMA P.C. ET AL: "Therapeutic uses of magnesium.", INDIAN JOURNAL OF PHARMACOLOGY, (1995) 27/1 (7-13). ISSN: 0253-7613 CODEN: INJPD2, India, XP002080012 *

Also Published As

Publication number Publication date
WO1998047497A2 (fr) 1998-10-29

Similar Documents

Publication Publication Date Title
EP2123665A3 (fr) Inhibiteurs de l'enzyme de conversion d'interleukine-1$g(b)
CA2289851A1 (fr) Composes et methodes d'inhibition de l'expression de vcam-1
EP1018517A3 (fr) Agents liants au CD23 pour le traitement des maladies inflammatoires, autoimmunes ou allergiques
CA2356380A1 (fr) Effets immunosuppresseurs de derives de la pteridine
WO2003034984A9 (fr) Compositions et procedes pour le diagnostic et le traitement d'affections intestinales inflammatoires
EP1762557A3 (fr) Mediateurs lipidiques actives par l'aspirine
HK1041637A1 (zh) Valdecoxib频谱
WO2002080850A3 (fr) Agents gonflants utilises comme agents de satiete
EP1389465A3 (fr) Utilisation d'un extrait de feuilles de Olea Europaea comme agent antiradicalaire
EA200100732A1 (ru) Противовоспалительные и иммуносупрессорные соединения, ингибирующие клеточную адгезию
CA2416900A1 (fr) L'utilisation combine d'un inhibiteur des lipases et d'un sequestrant d'acide biliaire pharmaceutiquement acceptable pour le traitement des maladies associees avec les niveaux eleves de cholesterol dans le plasma
EP2060255A3 (fr) Procédés et compositions pour la prévention et le traitement de maladie inflammatoire, maladie auto-immune, et rejet d'implant
AU2001245977A1 (en) Method and composition for preventing or reducing the symptoms of menopause
EP1443935A4 (fr) Traitement d'une maladie infectieuse a l'aide d'inhibiteurs de la famille ced-3/ice (enzyme de conversion de l'interleukine-1 beta)
AU4583597A (en) Novel tricyclic compounds for the inhibition of the ice/ced-3 protease family of enzymes
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
WO1998005777A3 (fr) BCL-xη, UNE NOUVELLE ISOFORME DE BCL-x, ET UTILISATIONS ASSOCIEES
WO1998047497A3 (fr) Methodes et compositions afferentes aux fins de la prevention et du traitement de troubles immunologiques, de maladies et d'infections a caractere inflammatoire
AU5006499A (en) Compositions and methods for the treatment or prevention of pulmonary infections
WO2003093242A3 (fr) Composes polycycliques a 5 elements substitues pour l'inhibition selective de la cascade de reactions dans la coagulation sanguine
AU2001247471A1 (en) Compositions and methods of treating, reducing, and preventing cardiovascular diseases and disorders with polymethoxyflavones
CA2534303A1 (fr) Composes de nitrone aryle bicycliques et heteroaromatiques, promedicaments et compositions pharmaceutiques de ces composes, destines a traiter des troubles chez les humains
HUP0204209A3 (en) Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms
WO2003024474A3 (fr) Agent anti-inflammatoire
AU7150598A (en) Methods and compositions for the prevention and treatment of immunological disorders, inflammatory diseases and infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998546329

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA